市場調查報告書

口腔粘膜炎的全球市場:2020年-2027年

Global Oral Mucositis Market - 2020-2027

出版商 DataM Intelligence 商品編碼 955332
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
口腔粘膜炎的全球市場:2020年-2027年 Global Oral Mucositis Market - 2020-2027
出版日期: 2020年08月27日內容資訊: 英文
簡介

口腔粘膜炎(OM),是口和喉嚨的粘膜潰瘍和炎症。是頭頸癌症的治療上接受放射線治療和化療的患者來說一般的副作用,成為嚴重的併發症。接受化療的患者約有40%和接受放射線治療的患者幾乎全部發生口腔粘膜炎。嚴重的OM併發症中,包含不堪忍受的疼痛和炎症,感染疾病風險的增加,營養失調,脫水,表達困難,毒品的使用增加等。放著不治療的話,這些侵蝕可能導致威脅生命的感染。口腔粘膜炎,透過切片檢查和真菌檢驗等各種檢驗診斷。 OM的治療所使用的產品,有口內清洗液,止痛藥,水溶性潤滑劑,刺激少的清洗劑,粘膜塗料劑等。

本報告提供全球OM市場調查,市場力學,產業分析,各原因,各治療法,各終端用戶,各地區的分析,競爭情形,企業簡介等資訊。

目錄

第1章 調查手法和範圍

  • 調查手法
  • 調查目的和範圍

第2章 市場定義和概要

第3章 摘要整理

  • 各原因市場
  • 各治療法市場
  • 各終端用戶市場
  • 地區市場

第4章 市場力學

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 產業分析

  • 波特的五力分析
  • 流行病學
  • 開發平台分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 未支援的需求

第6章 各原因的市場分析

  • 簡介
  • 市場規模和與前一年同期比較成長率分析
  • 市場魅力指數
    • 化療*
    • 放射線治療
    • 造血幹細胞移植

第7章 各治療法的市場分析

  • 簡介
  • 市場規模和與前一年同期比較成長率分析
  • 市場魅力指數
    • 漱口水*
    • 生長因子
    • 低等級雷射治療(LLLT)
    • 冷凍治療
    • 其他

第8章 各終端用戶的市場分析

  • 簡介
  • 市場規模和與前一年同期比較成長率分析
  • 市場魅力指數
    • 醫院*
    • 牙科醫院
    • 腫瘤治療中心
    • 研究機關
    • 其他

第9章 各地區的市場分析

  • 簡介
  • 市場規模和與前一年同期比較成長率分析
  • 市場魅力指數
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東、非洲

第10章 競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • 合併和收購分析

第11章 企業簡介

  • Daewoong Pharmaceutical Co.*
  • EUSA Pharma Inc.
  • Soligenix, Inc.
  • Sunstar Suisse SA
  • Swedish Orphan Biovitrum Ltd.
  • Amgen Inc.
  • Bausch Health
  • EKR Therapeutics, Inc.
  • Access Pharmaceuticals, Inc.
  • Eisai Inc.
  • BioAlliance Pharma SA.
  • Camurus AB
  • Moberg Pharma AB

第12章 主要調查結果

第13章 DataM Intelligence

目錄

Market Overview

Oral Mucositis (OM) is an ulceration and inflammation of the mucosal membranes in the mouth and throat. It is a common side effect and serious complication for patients receiving radiation and chemotherapy with head and neck cancer treatments. About 40% of chemotherapy and all radiation patients develop oral mucositis. Serious OM complications include intolerable pain and inflammation, increased risk of infections, malnutrition, dehydration, difficulty speaking, and increased use of narcotics. If left untreated, these sores can lead to life-threatening infections. Oral mucositis is diagnosed through various tests, including biopsy and fungal testing. Antiseptic mouth rinses, pain killer medicines, water-soluble lubricating agents, bland rinses, and mucosal coating agents are some of the products used for the treatment of OM.

The global oral mucositis market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Market Dynamics

The global oral mucositis market growth is majorly driven by the rising incidences of head and neck cancer. The annual incidence of HNC in the U.S. and Europe is approximately 150,000 and 750,000 cases globally. Approximately 60 to 70% of these patients will develop Severe Oral Mucositis (SOM). The side-effects of radiation effects and cytotoxic chemotherapy agents on oral mucosa lead to oral mucositis. As per the National Institutes of Health estimates, over 400,000 patients are diagnosed with oral mucositis annually in the United States. With the increasing prevalence of cancer patients globally, the market for oral mucositis therapeutics is also growing. Hence, the demand for treatment of oral mucositis is rapidly growing, which is expected to drive the market growth over the forecast period.

In addition, increasing clinical trial and adoption of collaboration strategies are enhancing oral mucositis therapeutics pipeline. As of March 2019, the oral mucositis therapeutics pipeline comprised more than twenty drugs (in addition to nine marketed drugs) in different stages of development. In June 2020, Soligenix, Inc., a biopharmaceutical company developing and commercializing products to treat rare diseases, has completed patient enrollment in its Phase 3 DOM-INNATE study for SGX942 (dusquetide) for the treatment of oral mucositis (OM) in head and neck cancer (HNC) patients. With the enrollment completed, top-line results are expected in the fourth quarter of 2020.

Growing research to develop new drugs for oral mucositis is also expected to boost market growth during the forecast period. For instance, in May 2020, researchers at the University of Arizona College of Pharmacy have reformulated Suramin, a 100-year old drug previously used to treat African sleeping sickness, to fight oral mucositis and diabetic foot ulcers. This breakthrough development has the potential to benefit thousands of patients whose current healing options are either partially effective or painful and invasive.

In July 2020, Innovation Pharmaceuticals, a clinical-stage biopharmaceutical company, reported the development to research into Brilacidin as a potential treatment for COVID-19. Brilacidin is being evaluated at a U.S. Regional Biocontainment Laboratory (RBL) and has consistently demonstrated robust in vitro antiviral properties against SARS-CoV-2, the novel coronavirus responsible for COVID-19.

However, the issuance of patents and long stringent approvals for products in the form of grants and designations from regulatory bodies, including the U.S. Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the National Institutes of Health (NIH), among others is a slowing down the market growth.

Segment Analysis

The global oral mucositis market is segmented by its cause into chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. Among these, the oral mucositis caused by chemotherapy segment is expected to hold a major share in the market as chemotherapy is widely used as a treatment method for cancer. For instance, as per the U.S. Department of Health & Human Services, every year, more than 650,000 cancer patients receive chemotherapy in an outpatient oncology clinic in the U.S.

The oral mucositis therapeutics market includes several kinds of drug formulations and treatments such as cryotherapy, growth factors, antioxidants, anti-inflammatory agents, low-level laser therapy (LLLT), mouthwashes, barriers and coating agents. Some of the approved drugs for the treatment of oral mucositis include Kepivance, GelX, NeutraSal, Easyef, and Caphosol. On May 4th 2020, the U.S. WorldMeds, launched GELX ORAL GEL, a Zinc-Taurine bioactive barrier therapy for relief from oral pain associated with oral mucositis. GELX ORAL GEL is a bioactive therapy that can build an effective barrier against the pain and inflammation of oral mucositis. It biomechanically protects against intraoral pain; coating exposed nerve endings and open sores. Through a polyvinylpyrrolidone delivery system, which can improve the release rate and solubility of drugs, GELX supplies the mucosal environment with a bioactive Zinc-Taurine Complex that is known to hinder and delay the inflammatory cycle of oral mucositis.

SGX942 (Soligenix, Inc.), MuGard (Daewoong Pharmaceutical Co.), CVXL-0095, Nu-3, Brilacidin, among others are in the pipeline which are expected to further drive the oral mucositis therapeutics market over the forecast period. Also, A phase 2 trial of Brilacidin, as an oral rinse for prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer (HNC), met its primary and secondary endpoints, including reducing the incidence of SOM. The price for Brilacidin is anticipated at $5,000 to $10,000 per full course of treatment based on the large unmet need as well based on initial pricing for the only other O.M. drug ever approved (Palifermin, hematopoietic stem cell transplantation, HSCT). Based on the company's estimates, the total Brilacidin oral rinse market opportunity annually in the U.S. and Europe would be approximately $600 million to $1.2 billion.

On the basis of end-user, the market is segmented into hospitals, oncology centres, dental clinics, and research institutes. The hospitals segment is expected to hold a major share in the market due to its close association with cancer availability of all possible treatment options.

Geographical Analysis

North America region is dominating the global oral mucositis market accounting for the largest market share in 2019, owing to huge funding and investments for the development of new products for the treatment of the condition. For instance, according to the American Society of Clinical Oncology (ASCO), head and neck cancer account for about 4% of all cancers in the US. In 2019, an estimated 65,410 people will develop head and neck cancer. High cases of cancer in the US and Canada is expected to drive the market growth. In addition, rising expenses in research & development by healthcare bodies to improve the treatment of oral mucositis is expected to fuel the growth of the market in this region.

Europe is estimated to hold second largest market share in the global oral mucositis market, due to the availability of advanced healthcare system, rise in cancer cases, and the expansion of major companies in this region. For instance, in April 2016, EUSA Pharma has acquired the global rights to next-generation oncology supportive care product Arcoral Tab from Arcoral Pharma.

The Asia-Pacific oral mucositis market is projected to grow at the fastest CAGR, due to the rising prevalence of cancer and progressing government initiatives for healthcare reforms. The market in the Middle East & Africa is projected to account for the least share of the global market due to low per capita disposable income in the region.

Competitive Landscape

The oral mucositis market is highly competitive and consists of several major players and emergence of new players in the market. Some of the key players which are contributing to the growth of the market are EUSA Pharma Inc., Daewoong Pharmaceutical Co., Soligenix, Inc., Sunstar Suisse SA, Swedish Orphan Biovitrum Ltd., Amgen Inc., Bausch Health, EKR Therapeutics, Inc., Access Pharmaceuticals, Inc., Eisai Inc., Innovation Pharmaceuticals, Moberg Pharma AB, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the oral mucositis market globally. For instance,

  • In February 2019, Innovation Pharmaceuticals received new patent for compounds for use in treatment of oral mucositis. The patent covers methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts.
  • In December 2019, Forward Science received FDA Clearance for Orapeutic, a non-opioid oral pain relief gel.

Why Purchase the Report?

  • Visualize the composition of the oral mucositis market segmentation by treatment, cause, and end-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in oral mucositis market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of oral mucositis market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global oral mucositis market report would provide an access to an approx. 61 market data table, 56 figures and 280 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Oral Mucositis market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Oral Mucositis market - Market Definition and Overview

3. Global Oral Mucositis market - Executive Summary

  • 3.1. Market Snippet by Cause
  • 3.2. Market snippet by Treatment
  • 3.3. Market snippet by End-User
  • 3.4. Market Snippet by Region

4. Global Oral Mucositis market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing incidence of head & neck cancer
      • 4.1.1.2. Rising R&D investments
      • 4.1.1.3. Growing number of pipeline drugs
      • 4.1.1.4. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Availability of alternative treatment
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Oral Mucositis market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs

6. Global Oral Mucositis market - By Cause

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause Segment
  • 6.3. Market Attractiveness Index, By Cause Segment
    • 6.3.1. Chemotherapy*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Radiotherapy
    • 6.3.3. Hematopoietic Stem Cell Transplantation

7. Global Oral Mucositis market - By Treatment

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 7.3. Market Attractiveness Index, By Treatment Segment
    • 7.3.1. Mouth Wash*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Growth Factors
    • 7.3.3. Low-level laser therapy (LLLT)
    • 7.3.4. Cryotherapy
    • 7.3.5. Others

8. Global Oral Mucositis market - By End-Users

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users Segment
  • 8.3. Market Attractiveness Index, By End-Users Segment
    • 8.3.1. Hospitals*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Dental Clinics
    • 8.3.3. Oncology Centers
    • 8.3.4. Research Institutes
    • 8.3.5. Others

9. Global Oral Mucositis market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Global Oral Mucositis market - Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Oral Mucositis market- Company Profiles

  • 11.1. Daewoong Pharmaceutical Co.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. EUSA Pharma Inc.
  • 11.3. Soligenix, Inc.
  • 11.4. Sunstar Suisse SA
  • 11.5. Swedish Orphan Biovitrum Ltd.
  • 11.6. Amgen Inc.
  • 11.7. Bausch Health
  • 11.8. EKR Therapeutics, Inc.
  • 11.9. Access Pharmaceuticals, Inc.
  • 11.10. Eisai Inc.
  • 11.11. BioAlliance Pharma SA.
  • 11.12. Camurus AB
  • 11.13. Moberg Pharma AB

LIST NOT EXHAUSTIVE

12. Global Oral Mucositis market - Premium Insights

13. Global Oral Mucositis market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us